Cargando…

Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer

SIMPLE SUMMARY: Pancreatic cancer is a devastating disease with a 5-year survival rate of 12%. Only about 20% of patients are candidates for curative surgery, while the majority receive palliative chemotherapy or best supportive care. Recently, testing chemotherapeutical agents on patient-derived 3-...

Descripción completa

Detalles Bibliográficos
Autores principales: Grützmeier, Simon Ezban, Kovacevic, Bojan, Vilmann, Peter, Rift, Charlotte Vestrup, Melchior, Linea Cecilie, Holmström, Morten Orebo, Brink, Lene, Hassan, Hazem, Karstensen, John Gásdal, Grossjohann, Hanne, Chiranth, Deepthi, Toxværd, Anders, Hansen, Carsten Palnæs, Høgdall, Estrid, Hasselby, Jane Preuss, Klausen, Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377599/
https://www.ncbi.nlm.nih.gov/pubmed/37509338
http://dx.doi.org/10.3390/cancers15143677
_version_ 1785079557355732992
author Grützmeier, Simon Ezban
Kovacevic, Bojan
Vilmann, Peter
Rift, Charlotte Vestrup
Melchior, Linea Cecilie
Holmström, Morten Orebo
Brink, Lene
Hassan, Hazem
Karstensen, John Gásdal
Grossjohann, Hanne
Chiranth, Deepthi
Toxværd, Anders
Hansen, Carsten Palnæs
Høgdall, Estrid
Hasselby, Jane Preuss
Klausen, Pia
author_facet Grützmeier, Simon Ezban
Kovacevic, Bojan
Vilmann, Peter
Rift, Charlotte Vestrup
Melchior, Linea Cecilie
Holmström, Morten Orebo
Brink, Lene
Hassan, Hazem
Karstensen, John Gásdal
Grossjohann, Hanne
Chiranth, Deepthi
Toxværd, Anders
Hansen, Carsten Palnæs
Høgdall, Estrid
Hasselby, Jane Preuss
Klausen, Pia
author_sort Grützmeier, Simon Ezban
collection PubMed
description SIMPLE SUMMARY: Pancreatic cancer is a devastating disease with a 5-year survival rate of 12%. Only about 20% of patients are candidates for curative surgery, while the majority receive palliative chemotherapy or best supportive care. Recently, testing chemotherapeutical agents on patient-derived 3-dimensional cultures (organoids) of cancer cells has provided hope that personalized treatment may soon become a reality. However, most of these models only include tumor cells and not cells of the supporting tissue, which have been shown to play a critical role in cancer progression. In this study, we created a co-culture including both tumor and stromal cells from endoscopic ultrasound-guided biopsies and showed that an interaction occurs between the cell types in our model. It may therefore be a step towards better prediction of therapeutic response in the future. We also discuss the limitations of creating these types of models by using endoscopic biopsies from primary tumors. ABSTRACT: Cancer-associated fibroblasts (CAFs) have been shown to impact the chemosensitivity of patient-derived tumor organoids (PDTOs). However, the published literature comparing PDTO response to clinical outcome does not include CAFs in the models. Here, a co-culture model was created using PDTOs and CAFs derived from endoscopic ultrasound-guided fine-needle biopsies (EUS-FNBs) for potential use in drug screening applications. Co-cultures were established, and growth was compared to monocultures using image metrics and a commercially available assay. We were able to establish and expand validated malignant PDTOs from 19.2% of adenocarcinomas from EUS-FNBs. CAFs could be established from 25% of the samples. The viability of PDTOs in the mixed cell co-culture could be isolated using image metrics. The addition of CAFs promoted PDTO growth in half of the established co-cultures. These results show that co-cultures can be established from tiny amounts of tissue provided by EUS-FNB. An increased growth of PDTOs was shown in co-cultures, suggesting that the present setup successfully models CAF–PDTO interaction. Furthermore, we demonstrated that standard validation techniques may be insufficient to detect contamination with normal cells in PDTO cultures established from primary tumor core biopsies.
format Online
Article
Text
id pubmed-10377599
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103775992023-07-29 Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer Grützmeier, Simon Ezban Kovacevic, Bojan Vilmann, Peter Rift, Charlotte Vestrup Melchior, Linea Cecilie Holmström, Morten Orebo Brink, Lene Hassan, Hazem Karstensen, John Gásdal Grossjohann, Hanne Chiranth, Deepthi Toxværd, Anders Hansen, Carsten Palnæs Høgdall, Estrid Hasselby, Jane Preuss Klausen, Pia Cancers (Basel) Article SIMPLE SUMMARY: Pancreatic cancer is a devastating disease with a 5-year survival rate of 12%. Only about 20% of patients are candidates for curative surgery, while the majority receive palliative chemotherapy or best supportive care. Recently, testing chemotherapeutical agents on patient-derived 3-dimensional cultures (organoids) of cancer cells has provided hope that personalized treatment may soon become a reality. However, most of these models only include tumor cells and not cells of the supporting tissue, which have been shown to play a critical role in cancer progression. In this study, we created a co-culture including both tumor and stromal cells from endoscopic ultrasound-guided biopsies and showed that an interaction occurs between the cell types in our model. It may therefore be a step towards better prediction of therapeutic response in the future. We also discuss the limitations of creating these types of models by using endoscopic biopsies from primary tumors. ABSTRACT: Cancer-associated fibroblasts (CAFs) have been shown to impact the chemosensitivity of patient-derived tumor organoids (PDTOs). However, the published literature comparing PDTO response to clinical outcome does not include CAFs in the models. Here, a co-culture model was created using PDTOs and CAFs derived from endoscopic ultrasound-guided fine-needle biopsies (EUS-FNBs) for potential use in drug screening applications. Co-cultures were established, and growth was compared to monocultures using image metrics and a commercially available assay. We were able to establish and expand validated malignant PDTOs from 19.2% of adenocarcinomas from EUS-FNBs. CAFs could be established from 25% of the samples. The viability of PDTOs in the mixed cell co-culture could be isolated using image metrics. The addition of CAFs promoted PDTO growth in half of the established co-cultures. These results show that co-cultures can be established from tiny amounts of tissue provided by EUS-FNB. An increased growth of PDTOs was shown in co-cultures, suggesting that the present setup successfully models CAF–PDTO interaction. Furthermore, we demonstrated that standard validation techniques may be insufficient to detect contamination with normal cells in PDTO cultures established from primary tumor core biopsies. MDPI 2023-07-19 /pmc/articles/PMC10377599/ /pubmed/37509338 http://dx.doi.org/10.3390/cancers15143677 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Grützmeier, Simon Ezban
Kovacevic, Bojan
Vilmann, Peter
Rift, Charlotte Vestrup
Melchior, Linea Cecilie
Holmström, Morten Orebo
Brink, Lene
Hassan, Hazem
Karstensen, John Gásdal
Grossjohann, Hanne
Chiranth, Deepthi
Toxværd, Anders
Hansen, Carsten Palnæs
Høgdall, Estrid
Hasselby, Jane Preuss
Klausen, Pia
Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer
title Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer
title_full Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer
title_fullStr Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer
title_full_unstemmed Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer
title_short Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer
title_sort validation of a novel eus-fnb-derived organoid co-culture system for drug screening in patients with pancreatic cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377599/
https://www.ncbi.nlm.nih.gov/pubmed/37509338
http://dx.doi.org/10.3390/cancers15143677
work_keys_str_mv AT grutzmeiersimonezban validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT kovacevicbojan validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT vilmannpeter validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT riftcharlottevestrup validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT melchiorlineacecilie validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT holmstrommortenorebo validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT brinklene validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT hassanhazem validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT karstensenjohngasdal validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT grossjohannhanne validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT chiranthdeepthi validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT toxværdanders validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT hansencarstenpalnæs validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT høgdallestrid validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT hasselbyjanepreuss validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer
AT klausenpia validationofanoveleusfnbderivedorganoidcoculturesystemfordrugscreeninginpatientswithpancreaticcancer